We have been through a lot of development in the field of biological science. From all the progress we have made, we evolve into more resilient beings. The main concern for studying natural sciences is to examine the various aspects of vital processes of every living thing. Another fundamental reason is to develop biological solutions that will improve and sustain the quality of life of humans, animals, and plants.
Because of biosciences, we accomplish things that will make our life and the world better. Biologists have made medicines, helped improve agriculture, and made breakthroughs in creating solutions to global problems. From simple to complicated, the tools are valuable in manufacturing different types of products such as hospital equipment, surgical supplies, advanced diagnostic imaging systems, orthopedic implants, and much more. With the combination of human and machine intelligence, discovering new medicines and therapeutics have empowered us to take steps towards advancing sciences.
Engine Biosciences is one such company as it is currently utilizing machines for drug discovery. They are a biotech company that digitizes and examines complex biology to discover and expand medicines to save lives. With the help of technology, diseases can be cured more efficiently.
Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics https://t.co/18RDIu3i13
— Polaris Partners (@PolarisVC) May 27, 2021
What our future holds
As we know, technology is prevalent in our period, and biologists utilize these instruments to have an accurate analysis in making compounds that they apply to the world. Until this day, biologists continue to innovate and apply advanced technologies to provide accurate, efficient, and safe compounds that will make living easier, such as Engine Biosciences.
As 20,000 to 25,000 genes interact in many ways with one another inside a human body, diseases occur because of the multiple complications of the network of these genes and make it impossible for humans to analyze by themselves. Good thing that Engine Biosciences has a specialized platform to provide solutions called NetMAPPR. This generates detailed data concerning gene networks, analyzes billions of gene interactions, and brings precise results that are confirmed through carefully planned tests and also through combinatorial genetics platform, CombiGEM.
With careful research and gathering of data, the Engine Biosciences’ machine will make medically accurate drugs that are handled by scientists and developers that have professional experience in drug discovery. The development of the field is impressive to witness as it enhances the therapeutic instruments with cell and gene therapies, small molecules, antibodies, and more advanced technologies.
Engine Biosciences unveiled its first major VC round with a $43 million Series A. With the new funds, CEO Jeffrey Lu expects Engine has enough runway to get its lead program into its first clinical trial by 2023.https://t.co/qAL5CBO9a0
— Endpoints News (@endpts) May 26, 2021
Conclusion
Hopefully, more innovations like Engine Biosciences will continue to evolve the Medtech field. The careful process of delivering quality care to people comes with medical and testing labs that critically analyze data to bring medical imaging services for healthcare providers. This includes drug development and analysis work for pharmaceutical companies and research organizations.
Engine Biosciences ensures that clinical assessment, engineering, quality assurance, product design, legal counsel, IT services, and training are all reliable for bringing the best developments of medicines and therapeutics. More importantly, their development of software and technology can expand the digital health space’s opportunities that the bioscience industry provides. This will hopefully decrease health care costs, improve patient results, and increase access to care.
Photo credit: The feature image is only symbolic and has been taken by Julia Koblitz.
